(Methyl-{3-[4-(naphthalen-2-yloxy)-phenoxy]-3-phenyl-propyl}-amino)-acetic acid | 766503-86-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (Methyl-{3-[4-(naphthalen-2-yloxy)-phenoxy]-3-phenyl-propyl}-amino)-acetic acid
• 英文别名: 2-[Methyl-[3-(4-naphthalen-2-yloxyphenoxy)-3-phenylpropyl]amino]acetic acid
• CAS: 766503-86-0
• 化学式: C₂₈H₂₇NO₄
• 分子量: 441.527
• InChiKey: TXMHANVDJPOBFW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  33
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  59
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Substituted aromatic ethers as inhibitors of glycine transport
  申请人：Pfizer Inc.

  公开号：US20030013887A1

  公开（公告）日：2003-01-16

  This invention relates to a series of substituted aromatic ethers of the formula I 1 wherein ring A and X and Y are defined as in the specification, that exhibit activity as glycine transport inhibitors, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their use for the enhancement of cognition and the treatment of the positive and negative symptoms of schizophrenia and other psychoses in mammals, including humans.

  这项发明涉及一系列符合以下式I1的取代芳香醚，其中环A和X和Y的定义如规范中所述，它们表现出作为甘氨酸转运抑制剂的活性，它们的药学上可接受的盐、含有它们的药物组合物，以及它们用于增强认知和治疗哺乳动物，包括人类，的精神分裂症和其他精神病的正性和负性症状。
• SUBSTITUTED AROMATIC ETHERS AS INHIBITORS OF GLYCINE TRANSPORT
  申请人：Pfizer Products Inc.

  公开号：EP1406861A1

  公开（公告）日：2004-04-14
• US6566550B2
  申请人：——

  公开号：US6566550B2

  公开（公告）日：2003-05-20
• US6784299B2
  申请人：——

  公开号：US6784299B2

  公开（公告）日：2004-08-31
• [EN] SUBSTITUTED AROMATIC ETHERS AS INHIBITORS OF GLYCINE TRANSPORT<br/>[FR] ETHERS AROMATIQUES SUBSTITUES INHIBITEURS DE TRANSPORT DE LA GLYCINE
  申请人：PFIZER PROD INC

  公开号：WO2003000646A1

  公开（公告）日：2003-01-03

  This invention relates to a series of substituted aromatic ethers of the formula (I), wherein ring A and X and Y are defined as in the specification, that exhibit activity as glycine transport inhibitors, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their use for the enhancement of cognition and the treatment of the positive and negative symptoms of schizophrenia and other psychoses in mammals, including humans.